Zura Bio Limited is focused on developing innovative therapies for serious autoimmune and inflammatory disorders, with a particular emphasis on dual-pathway biology. Their lead candidate, tibulizumab (ZB-106), is a first-in-class anti-IL-17 and anti-BAFF dual antagonist. This unique therapeutic approach allows tibulizumab to simultaneously target two distinct soluble ligands, potentially enhancing its efficacy in treating conditions driven by both T-cell and B-cell signaling. The company has conducted multiple Phase 1b studies, demonstrating an acceptable safety profile and a half-life of 26.9 days for tibulizumab. Upcoming clinical trials aim to evaluate its effectiveness in systemic sclerosis and hidradenitis suppurativa, addressing significant unmet medical needs in these areas.

In addition to tibulizumab, Zura Bio is developing other therapeutic candidates, including crebankitug (ZB-168) and torudokimab (ZB-880), with the goal of providing effective treatment options across various autoimmune conditions. The company's strategy highlights the importance of addressing both T-cell and B-cell driven diseases, which are often inadequately treated by existing therapies. By leveraging their dual-pathway approach, Zura Bio aims to improve clinical outcomes for patients suffering from these complex disorders, ultimately enhancing their quality of life through innovative and effective treatment solutions.

United States

Zura Bio is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders. Currently, Zura Bio is developing three assets which have completed phase 1/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), torudokimab (ZB-880), and ZB-168 with a goal of demonstrating their efficacy, safety, and dosing convenience in immune and inflammatory disorders. Zura Bio is headquartered in Henderson, NV with team members in the UK and USA.

Zura Bio Limited

Company Details